Roche: FDA Approves Treatment for Advanced ER+, HER2- Breast Cancer with ESR1 Mutations

Berlin, Germany – February 22, 2026 – Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for inavolisib, an oral treatment for advanced breast cancer. The drug is intended for adult patients with hormone receptor-positive (HR+), HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have progressed following prior endocrine-based therapy. This marks a significant step forward in the potential treatment options for a challenging subset of breast cancer patients.

The FDA’s decision to review inavolisib comes on the heels of promising clinical trial data demonstrating its potential to significantly delay disease progression when added to standard care. Breast cancer remains a leading cause of cancer-related deaths among women globally, and the development of new therapies, particularly those targeting specific genetic mutations, is crucial. Approximately 40% of HR+/HER2- breast cancer patients, which accounts for around 73% of all breast cancer cases, harbor a PIK3CA mutation, making this a substantial patient population that could benefit from inavolisib.

Understanding Inavolisib and the PIK3CA Mutation

Inavolisib is a PI3Kα inhibitor, designed to target the PIK3CA gene mutation. This mutation disrupts normal cellular signaling pathways, leading to uncontrolled cell growth and contributing to resistance to hormone therapy, a cornerstone of treatment for HR+ breast cancer. When the PIK3CA gene is mutated, it can override the effects of endocrine therapy, allowing the cancer to continue growing. By inhibiting PI3Kα, inavolisib aims to restore sensitivity to hormone therapy and slow disease progression.

The clinical development of inavolisib has focused on patients who have developed resistance to endocrine therapy. These patients often have limited treatment options, making the potential of a new targeted therapy particularly impactful. The NDA submission is based on data from the INAVO120 clinical trial, a Phase 3 study that evaluated inavolisib in combination with palbociclib (Ibrance) and fulvestrant (Faslodex).

Promising Results from the INAVO120 Trial

The results of the INAVO120 trial, presented at a recent medical conference, showed a significant improvement in progression-free survival (PFS) for patients treated with inavolisib in addition to palbociclib and fulvestrant. Patients receiving the combination therapy experienced a median PFS of 15.0 months, more than double the 7.3 months observed in patients receiving palbociclib and fulvestrant alone. The risk of disease worsening or death was reduced by 57% in the inavolisib arm of the study.

While overall survival (OS) data was still maturing at the time of the initial analysis, preliminary results indicated a positive trend, and further analysis is ongoing. These findings suggest that inavolisib could not only delay disease progression but too potentially extend the lives of patients with this aggressive form of breast cancer. The FDA granted Priority Review to the application, which means the agency will expedite its review process, recognizing the unmet medical need in this patient population.

The FDA Review Process and Timeline

The FDA’s Priority Review designation indicates that the agency recognizes the potential of inavolisib to provide a significant benefit to patients. The Prescription Drug User Fee Act (PDUFA) date for the FDA’s decision is November 27, 2026. This means the agency is expected to announce its decision on or before this date. The FDA will thoroughly evaluate the data submitted by Roche, including the clinical trial results, manufacturing information, and safety data, to determine whether to approve inavolisib for employ in the United States.

The FDA review process involves a multidisciplinary team of experts who will assess the drug’s benefits and risks. If approved, inavolisib would represent a new treatment option for patients with PIK3CA-mutated, HR+, HER2- advanced breast cancer who have progressed after endocrine therapy. This approval would also validate the growing importance of precision medicine in cancer treatment, where therapies are tailored to the specific genetic characteristics of a patient’s tumor.

Roche’s Position in the Breast Cancer Treatment Landscape

Roche has long been a leader in the development of breast cancer therapies, with established treatments like Herceptin (trastuzumab) and Perjeta (pertuzumab). However, the company has recently faced increasing competition in the HER2-positive breast cancer space, particularly from Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan). The FDA’s recent decision to grant priority review to Enhertu in combination with Perjeta for first-line HER2-positive breast cancer treatment signals a shift in the competitive landscape.

Despite this competition, Roche remains committed to innovation in breast cancer treatment. The development of inavolisib represents a strategic move to address the needs of patients with specific genetic mutations, offering a more targeted approach to therapy. The company’s global product development leader, Levi Garraway, emphasized the potential of inavolisib to extend the survival of patients with PIK3CA-mutated metastatic breast cancer.

Looking Ahead: The Future of Breast Cancer Treatment

The potential approval of inavolisib is part of a broader trend towards personalized cancer treatment. As our understanding of the genetic drivers of cancer grows, we are increasingly able to develop therapies that target specific mutations and pathways. This approach promises to improve treatment outcomes and reduce side effects by delivering the right drug to the right patient at the right time.

The ongoing research into PIK3CA mutations and the development of PI3Kα inhibitors like inavolisib are crucial steps in this direction. Further studies are needed to explore the potential of inavolisib in combination with other therapies and to identify biomarkers that can predict which patients are most likely to benefit from this treatment. The FDA’s decision in November 2026 will be closely watched by the medical community and, most importantly, by patients and their families who are seeking new hope in the fight against breast cancer.

Key Takeaways:

• Roche’s inavolisib is under FDA review for advanced breast cancer with a specific genetic mutation (PIK3CA).
• Clinical trial data shows inavolisib significantly improves progression-free survival when added to standard care.
• The FDA granted Priority Review, with a decision expected by November 27, 2026.
• Inavolisib represents a move towards personalized cancer treatment, targeting specific genetic drivers of the disease.

The next key date to watch is November 27, 2026, when the FDA is scheduled to announce its decision regarding the approval of inavolisib. We will continue to follow this story and provide updates as they develop into available. Share your thoughts and experiences in the comments below.